Abstract
OBJECTIVE: The purpose of this study was to develop three predictive models utilising clinical factors, radiomics features, and habitat features, to distinguish between nonclinically significant prostate cancer (csPCa) and clinically significant PCa (non-csPCa) on the basis of biparametric MRI (bp-MRI). METHODS: A total of 175 patients were enrolled, including 134 individuals with csPCa and 41 with non-csPCa. The clinical model was developed using optimal predictive factors obtained from univariable logistic regression and modelled through a random forest approach. Image acquisition and segmentation were performed first in the creation of both the radiomics model and the habitat model. The K-means clustering algorithm was then used exclusively for habitat generation in the development of the habitat model. Finally, feature selection and model construction were performed for both models. Model comparison and diagnostic efficacy assessment were conducted through receiver operating characteristic curve analysis, decision curve analysis (DCA), and calibration curve analysis. RESULTS: The habitat model outperformed both the radiomics model and the clinical model in distinguishing csPCa from non-csPCa patients. The AUC values of the habitat model in the training and test sets were 0.99 and 0.93, respectively. Furthermore, DCA and the calibration curves highlighted the superior clinical utility and greater predictive accuracy of the habitat model in comparison with the other two models. CONCLUSION: We developed a habitat-based radiomics model with a greater ability to distinguish between csPCa and non-csPCa on the basis of bp-MRI than a traditional radiomics model and clinical model. This introduces a novel approach for assessing the heterogeneity of PCa and offers urologists a quantitative, noninvasive method for preoperatively evaluating the aggressiveness of PCa.